Overview

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Status:
Completed
Trial end date:
2018-11-05
Target enrollment:
Participant gender:
Summary
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
Phase:
Phase 3
Details
Lead Sponsor:
Aldeyra Therapeutics, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions